Mylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Mylan received approval from FDA to market its desvenlafaxine extended-release (ER) tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Related: Game-changing depression drug on horizon
Desvenlafaxine ER tablets, 50 mg and 100 mg, had US sales of approximately $853 million for the 12 months ending January 31, 2017, according to IMS Health.
In addition, Teva Pharmaceuticals and Lupin received approval for their generic versions of Pristiq on March 1. Teva launched desvenlafaxine ER tablets in 25 mg, 50 mg, and 100 mg doses, while Lupin launched desvenlafaxine succinate ER tablets form in 50 mg and 100 mg.
Related: Industry pushes for faster generic approvals as costs rise
Pfizer will take a hit from the generic competition, and estimated that it will have about $578 million at risk this year due to patent expirations. Plus, in the fourth quarter of this year, Pfizer’s Viagra loses patent protection, which is expected to significantly claw into Pfizer’s estimated $1.2 billion in sales of the drug.
Pristiq was launched in 2008, as part of a class of serotonin-norepinephrine reuptake inhibitors (SNRIs). Pristiq affects the levels of norepinephrine and serotonin, which play a role in depression.
Read more: FDA approves first drug for Duchenne muscular dystrophy
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More